Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Statement of Comprehensive Income 

Allergan PLC, consolidated statement of comprehensive income

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income (loss) (5,265,100) (5,086,200) (4,118,900) 14,979,500 3,919,400
Foreign currency translation gains (losses) (151,800) (474,400) 1,248,000 (441,600) (129,900)
Net impact of other-than-temporary loss on investment in Teva securities 1,599,400
Impact of Teva Transaction 1,544,800
Unrealized gains (losses), net of tax 13,800 (38,100) 111,700 (1,647,500) 101,200
Other comprehensive income (loss), net of tax (138,000) (512,500) 2,959,100 (544,300) (28,700)
Comprehensive income (loss) (5,403,100) (5,598,700) (1,159,800) 14,435,200 3,890,700
Comprehensive income attributable to noncontrolling interest (5,900) (10,200) (6,600) (6,100) (4,200)
Comprehensive income (loss) attributable to ordinary shareholders (5,409,000) (5,608,900) (1,166,400) 14,429,100 3,886,500

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Net Income (Loss)
The net income exhibited significant volatility over the period. It was positive in 2015 and 2016, with an especially high peak in 2016. Subsequently, the company reported losses for three consecutive years from 2017 to 2019, with losses deepening slightly each year.
Foreign Currency Translation Gains (Losses)
Foreign currency translation effects were generally negative or minimal except in 2017 when a positive gain was noted. Both 2015 and 2016 showed moderate losses, with a return to losses in 2018 and 2019, though these were smaller in magnitude compared to the earlier years.
Net Impact of Other-Than-Temporary Loss on Investment in Teva Securities
This unique item appeared only in 2017, registering a substantial loss impact, which may have contributed to the negative net income in that year.
Impact of Teva Transaction
The impact related to the Teva transaction was recorded solely in 2016, showing a positive value that likely influenced the unusually high net income in that year.
Unrealized Gains (Losses), Net of Tax
Unrealized gains and losses fluctuated noticeably, with a loss in 2016, gains in 2015 and 2017, and relatively small fluctuations in 2018 and 2019. The pattern indicates variability in unrealized market gains or losses.
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive income also showed volatility, with a notable loss in 2016, a significant gain in 2017, and losses again in the last two years. This suggests swings in components such as foreign currency items, pension adjustments, or other non-operating items.
Comprehensive Income (Loss)
Comprehensive income mirrored the trends in net income, being positive in 2015 and 2016, with a peak in 2016 before turning negative in the subsequent years. The losses in later years increased in magnitude, reflecting the decline in overall financial performance.
Comprehensive Income Attributable to Noncontrolling Interest
The share of comprehensive income attributable to noncontrolling interests remained fairly small and negative throughout the period, with minor fluctuations but no clear trend.
Comprehensive Income (Loss) Attributable to Ordinary Shareholders
The comprehensive income attributable to ordinary shareholders closely tracked the overall comprehensive income, showing strong positive results in 2015 and 2016 before turning negative from 2017 onwards, indicating sustained challenges impacting shareholders' equity.